UroGen Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for UroGen Pharma (URGN).

Price Target Range — 13 Quarters

Analyst Consensus — 8 Analysts

7Buy

1Hold

Consensus RatingBuy# Analysts8Avg. Consensus PT$39Upside to Avg. PT+12.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 19, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$75
Aug 6, 2026	Guggenheim	Michael Schmitz	PT Raise	Buy	$42→$58
Aug 6, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$45→$75
Aug 5, 2026	TD Cowen	Tara Bancroft	PT Raise	Buy	$50→$60
Jul 21, 2026	Guggenheim	Brad Canino	PT Raise	Buy	$32→$42
Jul 16, 2026	Oppenheimer	Leland Gershell	PT Raise	Outperform→Outperformer	$40→$50
Jun 3, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$45
May 18, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$45
May 11, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$40→$45
May 7, 2026	Oppenheimer	Leland Gershell	PT Raise	Outperform	$34→$40
Mar 31, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$33
Mar 2, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$33
Jan 23, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$33
Jan 5, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$33
Oct 27, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$40
Oct 27, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$25
Oct 3, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$25
Aug 19, 2025	Piper Sandler	Kelsey Goodwin	Initiate	Overweight	$36
Aug 11, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$50→$40
Aug 7, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$25

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $75 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $75 price target.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58

Guggenheim analyst Michael Schmitz maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $42 to $58.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $75

HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $45 to $75.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on UroGen Pharma, Raises Price Target to $60

TD Cowen analyst Tara Bancroft maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $50 to $60.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $42

Guggenheim analyst Brad Canino maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $32 to $42.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperformer on UroGen Pharma, Raises Price Target to $50

Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperformer and raises the price target from $40 to $50.

Benzinga Newsdesk

UroGen Pharma Ltd

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

UroGen Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $75 Price Target

PRO
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58

PRO
HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $75

PRO
TD Cowen Maintains Buy on UroGen Pharma, Raises Price Target to $60

PRO
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $42

PRO
Oppenheimer Maintains Outperformer on UroGen Pharma, Raises Price Target to $50

People Also Watch

People Also Watch

UroGen Pharma Ltd

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

UroGen Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $75 Price Target

PROGuggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58

PROHC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $75

PROTD Cowen Maintains Buy on UroGen Pharma, Raises Price Target to $60

PROGuggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $42

PROOppenheimer Maintains Outperformer on UroGen Pharma, Raises Price Target to $50

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $75 Price Target

PRO
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58

PRO
HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $75

PRO
TD Cowen Maintains Buy on UroGen Pharma, Raises Price Target to $60

PRO
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $42

PRO
Oppenheimer Maintains Outperformer on UroGen Pharma, Raises Price Target to $50